
- /
- Supported exchanges
- / US
- / BPMC.NASDAQ
Blueprint Medicines Corp (BPMC NASDAQ) stock market data APIs
Blueprint Medicines Corp Financial Data Overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Blueprint Medicines Corp data using free add-ons & libraries
Get Blueprint Medicines Corp Fundamental Data
Blueprint Medicines Corp Fundamental data includes:
- Net Revenue: 562 M
- EBITDA: -158 367 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -1.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Blueprint Medicines Corp News

‘Stay Invested’: Wells Fargo Suggests 2 Stocks to Ride the Market Recovery
After a bruising spring that saw the stock market tumble under the weight of sweeping tariffs, stocks have mounted an impressive comeback. Since hitting a low on April 8, the S&P 500 has surged 17%, l...


3 High Growth Tech Stocks In The US Market
As the U.S. market navigates a complex landscape with the S&P 500 experiencing slight declines and Treasury yields on the rise, investors are closely monitoring legislative developments that could imp...

Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates
Shareholders of Blueprint Medicines Corporation (NASDAQ:BPMC) will be pleased this week, given that the stock price is up 19% to US$105 following its latest quarterly results. Revenues of US$149m repo...

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Blueprint Medicines (NASDAQ:BPMC) First Quarter 2025 Results Key Financial Results Revenue: US$149.4m (up 56% from 1Q 2024). Net income: US$496.0k (down 99% from 1Q 2024). Profit margin: 0.3% (down ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.